This inventor holds 1 USPTO granted patent. Top assignee: Pierre Fabre Medicament. Active years: 1999.
Company Filing History:
Years Active: 1999
Title: The Innovations of Stefan Stanghl
Introduction
Stefan Stanghl is a notable inventor based in Gorvik, Sweden. He has made significant contributions to the field of biotechnology, particularly in the area of recombinant DNA technology. His work has implications for the development of novel therapeutic proteins.
Latest Patents
Stanghl holds a patent for "Recombinant DNA coding for signal peptide, selective interacting - Tripartite recombinant DNA encoding fusion proteins." This patent describes a method for creating fusion proteins that include a signal peptide operable in Gram-positive bacteria, an immunogenic polypeptide, and a cell wall spanning and membrane anchoring sequence. The preferred polypeptides for this purpose include Staphylococcus protein A and Streptococcus protein G. This innovation has the potential to enhance the expression of therapeutic proteins on the surface of Gram-positive bacteria.
Career Highlights
Stanghl has been associated with Pierre Fabre Medicament, where he has contributed to various research initiatives. His expertise in recombinant DNA technology has positioned him as a valuable asset in the field of biotechnology. His work continues to influence the development of new therapeutic strategies.
Collaborations
Some of his notable coworkers include Per-Ångke Nygren and Marianne Hansson. Their collaborative efforts have further advanced the research and applications of recombinant DNA technologies.
Conclusion
Stefan Stanghl's innovative work in recombinant DNA technology exemplifies the impact of scientific research on biotechnology. His contributions are paving the way for future advancements in therapeutic protein development.